Paolos_Biotech_Notes_-_AKAO.pdfThis is the second in the new series for members, tentatively titled Paolo's Biotech Notes. To view the first article, and an introduction on the series, please click ...
1. Nature Biotechnology published the letter, which 165 biotech executives signed, that details the industry’s “deep concern and opposition to the executive order.” 2. The letter says of the nearly 69 ...
The U.S. excels at funding discovery and celebrating breakthroughs, then neglects the hard work of manufacturing them at ...
Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other industries as biotechnology has delivered only subpar investor returns. Only five ...
Third article in Paolo's Biotech Notes series. PDF attached and uploaded. Additionally, Paolo has provided a relevant timely article. ContraFect Corp (CFRX) has a promising pipeline with a potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback